News >

Addition of Daratumumab Triples Increase in MRD Conversion in Relapsed Myeloma

Wayne Kuznar
Published: Friday, Dec 16, 2016

Herve Avet-Loiseau, MD, PhD

Hervé Avet-Loiseau, MD, PhD

The addition of daratumumab (Darzalex) to standard-of-care regimens tripled the increase in conversion to negative minimal residual disease (MRD) status in the treatment of patients with relapsed/refractory multiple myeloma (RRMM), according to results of an assessment of MRD from the phase III CASTOR and POLLUX studies1. These findings were presented at the 2016 ASH Annual Meeting.

Patients with sustained MRD negativity over time showed significantly longer PFS with daratumumab plus Rd or Vd compared with Rd or Vd alone.
  1. Avet-Loisseau H, Casneuf T, Chiu C, et al. Evaluation of minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone. Presented at: American Society of Hematology 58th Annual Meeting; December 3-6, 2016; San Diego, CA. Abstract 246.
  2. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:1319-1331.
  3. Palumbo A, Chanan-Khan A, Wesiel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:754-766.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication